ACCOLADE INC (ACCD)

Get insights into the top gainers and losers of Friday's after-hours session.

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

ACCD Stock Earnings: Accolade Misses EPS, Beats Revenue for Q4 2024

ACCD stock results show that Accolade missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2024.

ACCD Stock Earnings: Accolade Misses EPS, Beats Revenue for Q4 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Accolade (NASDAQ:ACCD) just reported results for the fourth quarter of 2024.Acc...

Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2024

Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2024

SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal fourth quarter and full year...

Relative Strength Alert For Accolade

Relative Strength Alert For Accolade

Accolade To Present at Upcoming Investor Conferences

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor...

Alabama’s Fertility Ruling Raises Challenges for Stocks of Fertility Benefits Providers

The recent Alabama State Supreme Court ruling on frozen embryos could have national repercussions. Here's what you need to know about it.

Progyny stock slips after Alabama fertility ruling (NASDAQ:PGNY)

Progyny (PGNY) and Accolade (ACCD) drop after the Alabama Supreme Court ruled that frozen embryos can be considered children. Read more here.

Commit To Buy Accolade At $7.50, Earn 11.2% Annualized Using Options

Notable Tuesday Option Activity: AVGO, ACCD, CPRI

ACCD Stock Earnings: Accolade Beats EPS, Beats Revenue for Q3 2024

ACCD stock results show that Accolade beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.

ACCD Stock Earnings: Accolade Beats EPS, Beats Revenue for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Accolade (NASDAQ:ACCD) just reported results for the third quarter of 2024.Acco...

Accolade Announces Results for Fiscal Third Quarter 2024

Accolade Announces Results for Fiscal Third Quarter 2024

SEATTLE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal third quarter ended...

Accolade To Present at Upcoming Investor Conferences

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor...

Accolade To Present at Piper Sandler 35th Annual Healthcare Conference

SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it...

Accolade Announces Repurchase of $76.5 Million of 0.50% Convertible Senior Notes Due 2026

SEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it has entered into separate, privately negotiated...

Accolade To Present at Stephens Annual Investment Conference

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it...

Accolade Named to 2023 Deloitte Technology Fast 500™

/PRNewswire/ -- Accolade today announced it has been named to the Deloitte Technology Fast 500™, a ranking of the fastest-growing technology, media,...

Commit To Buy Accolade At $5, Earn 17% Annualized Using Options

1 Market-Beating Stock to Buy Near Its 52-Week High

This stock has been firing on all cylinders -- and it isn't about to stop.